Collectively, the mechanism of BAD inactivation by dysregulated PI3K/Akt signaling may be an important resistance mechanism in both PTEN‐deleted and PTEN–wild‐type prostate cancer and highlights a novel therapeutic strategy to increase apoptotic response to AR antagonists. This evidence concerns the gene AR and prostate carcinoma.